Psoriasis Clinical Trials in Atlanta
View 27 new treatments for Psoriasis in Atlanta, GA, and nearby areas, such as Sandy Springs. Every day, Power helps hundreds of psoriasis patients connect with leading medical research.Filter Results
Condition
All
How old are you?
Trial Phase
All
Trial Status
All
TAK-279 for Plaque Psoriasis
Takeda Clinic, Atlanta + 1 more
This trial is testing a new drug called TAK-279 to see if it can help people with moderate to severe plaque psoriasis. The study will compare TAK-279 to an existing treatment called apremilast, which is approved for the treatment of moderate to severe plaque psoriasis and psoriatic arthritis. The goal is to find out if TAK-279 can better reduce the skin problems associated with this condition.Show More
Verified
Recruiting
Phase 3
Est. 6 - 12 Weeks
Study Director
Study Director
Deucravacitinib for Psoriasis
Bristol-Myers Squibb Clinic, Snellville + 4 more
The purpose of this study is to evaluate the effect of deucravacitinib on quality of life (QoL) in participants with plaque psoriasis in a community setting.
Waitlist
Phase 4
Est. 3 - 6 Weeks
Bristol-Myers Squibb
Study Director
Subcutaneous Risankizumab for Psoriasis
AbbVie Clinic, Alpharetta + 1 more
Psoriasis (PsO) is a chronic disease characterized by marked inflammation of the skin that results in thick, red, scaly plaques. This study will assess how safe and effective risankizumab is in adult participants with moderate to severe genital psoriasis or moderate to severe scalp psoriasis. Adverse events and change in disease signs and symptoms will be monitored. Risankizumab (Skyrizi) is a drug being studied for the treatment of moderate to severe genital psoriasis or moderate to severe scalp psoriasis. Approximately 200 participants with moderate to severe genital psoriasis or moderate to severe scalp psoriasis will be enrolled across approximately 45 sites globally. The study will be broken up into 2 sub-studies by disease location, participants with moderate to severe genital psoriasis (Study G) and moderate to severe scalp psoriasis (Study S). In both sub-studies participants will receive subcutaneous (SC) injections of risankizumab during the 52 week treatment period, or SC injections of placebo risankizumab during the 16 week treatment period followed by SC injections of risankizumab during the 36 week treatment period, with an 8-week follow-up period after the 52 week treatment period. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.Show More
Recruiting
Phase 4
Est. 3 - 12 Weeks
ABBVIE INC.
Study Director
Bimekizumab for Psoriatic Arthritis
UCB Biopharma Clinic, Atlanta + 1 more
This trial is testing the safety and effectiveness of bimekizumab, a medication given as an injection under the skin. It is aimed at adults who have psoriatic arthritis, a condition that causes joint pain and swelling. Bimekizumab works by blocking proteins that cause inflammation, helping to reduce pain and swelling.Show More
Waitlist
No Placebo Trial
Phase 3
Est. 3 - 12 Weeks
UCB Cares
Study Director
Tildrakizumab for Psoriatic Arthritis
Sun Clinic, Decatur + 1 more
This trial is testing tildrakizumab, a medication that reduces inflammation, in patients with active Psoriatic Arthritis who haven't tried certain other treatments. It works by blocking a protein to help manage symptoms. Tildrakizumab is approved for treating moderate to severe plaque psoriasis.Show More
Waitlist
Phase 3
Est. 6 - 12 Weeks
Unregistered Study Lead
Research Team
Upadacitinib for Psoriatic Arthritis
AbbVie Clinic, Marietta + 2 more
The study objectives of Period 1 are to compare the efficacy, safety, and tolerability of upadacitinib 15 mg once daily (QD) and 30 mg QD versus placebo for the treatment of signs and symptoms in adults with moderately to severely active psoriatic arthritis (PsA) who have had an inadequate response or intolerance to biologic disease-modifying anti-rheumatic drug (bDMARD). The objective of Period 2 is to evaluate the long-term safety, tolerability and efficacy of upadacitinib 15 mg QD and 30 mg QD in participants who have completed Period 1.Show More
Waitlist
Phase 3
Est. 6 - 12 Weeks
AbbVie Inc.
Study Director
Risankizumab for Psoriatic Arthritis
AbbVie Clinic, Atlanta + 1 more
The purpose of this study is to evaluate the safety and efficacy of risankizumab in adults with moderately to severely active psoriatic arthritis (PsA).
Waitlist
Phase 3
Est. 3 - 12 Weeks
AbbVie Inc.
Study Director
Deucravacitinib for Psoriatic Arthritis
Bristol-Myers Squibb Clinic, Gainesville + 1 more
This trial is testing a new medication called deucravacitinib to see if it can help people with psoriatic arthritis who haven't tried advanced treatments. The medication works by reducing joint swelling and pain by blocking inflammation. Deucravacitinib is a new oral drug that has shown good results in previous studies for psoriasis.Show More
Waitlist
Phase 3
Est. 5 - 8 Weeks
Bristol-Myers Squibb
Study Director
Tildrakizumab SC Injection for Psoriatic Arthritis
Sun Clinic, Decatur + 1 more
An open label phase 3 study
Waitlist
No Placebo Trial
Phase 3
Est. 5 - 8 Weeks
Unregistered Study Lead
Research Team
Risankizumab for Psoriatic Arthritis
AbbVie Clinic, Atlanta + 1 more
The purpose of this study is to compare the safety and efficacy of risankizumab versus placebo in participants with moderately to severely active psoriatic arthritis (PsA).Show More
Waitlist
Phase 3
Est. 3 - 12 Weeks
ABBVIE INC.
Study Director
Page 1 of 3
Frequently Asked Questions
Explore related conditions